274 related articles for article (PubMed ID: 31306710)
1. The posttranslational modifications of Hippo-YAP pathway in cancer.
Yan F; Qian M; He Q; Zhu H; Yang B
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129397. PubMed ID: 31306710
[TBL] [Abstract][Full Text] [Related]
2. New insights into posttranslational modifications of Hippo pathway in carcinogenesis and therapeutics.
He M; Zhou Z; Shah AA; Hong Y; Chen Q; Wan Y
Cell Div; 2016; 11():4. PubMed ID: 27042197
[TBL] [Abstract][Full Text] [Related]
3. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
4. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
[TBL] [Abstract][Full Text] [Related]
5. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
6. Hippo signaling promotes JNK-dependent cell migration.
Ma X; Wang H; Ji J; Xu W; Sun Y; Li W; Zhang X; Chen J; Xue L
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1934-1939. PubMed ID: 28174264
[TBL] [Abstract][Full Text] [Related]
7. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the Hippo-YAP Pathway by Glucose Sensor O-GlcNAcylation.
Peng C; Zhu Y; Zhang W; Liao Q; Chen Y; Zhao X; Guo Q; Shen P; Zhen B; Qian X; Yang D; Zhang JS; Xiao D; Qin W; Pei H
Mol Cell; 2017 Nov; 68(3):591-604.e5. PubMed ID: 29100056
[TBL] [Abstract][Full Text] [Related]
9. PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis.
Xu W; Yang Z; Xie C; Zhu Y; Shu X; Zhang Z; Li N; Chai N; Zhang S; Wu K; Nie Y; Lu N
J Exp Clin Cancer Res; 2018 Aug; 37(1):198. PubMed ID: 30134988
[TBL] [Abstract][Full Text] [Related]
10. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
11. Hippo signaling dysfunction induces cancer cell addiction to YAP.
Han H; Yang B; Nakaoka HJ; Yang J; Zhao Y; Le Nguyen K; Bishara AT; Mandalia TK; Wang W
Oncogene; 2018 Dec; 37(50):6414-6424. PubMed ID: 30068939
[TBL] [Abstract][Full Text] [Related]
12. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer.
Wang T; Wang D; Sun Y; Zhuang T; Li X; Yang H; Zang Y; Liu Z; Yang P; Zhang C; Cui J; Fu M; Zhang S; Su P; Li Z; Zhu J; Ding Y
J Exp Clin Cancer Res; 2023 Nov; 42(1):297. PubMed ID: 37950281
[TBL] [Abstract][Full Text] [Related]
13. MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers.
Seo J; Kim MH; Hong H; Cho H; Park S; Kim SK; Kim J
Cancer Res; 2019 Dec; 79(24):6139-6152. PubMed ID: 31578200
[TBL] [Abstract][Full Text] [Related]
14. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
15. Genome-wide RNA interference screening reveals a COPI-MAP2K3 pathway required for YAP regulation.
Kim YJ; Jung E; Shin E; Hong SH; Jeong HS; Hur G; Jeong HY; Lee SH; Lee JE; Kim GH; Kim J
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):19994-20003. PubMed ID: 32747557
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.
Hsu PC; Miao J; Huang Z; Yang YL; Xu Z; You J; Dai Y; Yeh CC; Chan G; Liu S; Urisman A; Yang CT; Jablons DM; You L
J Cell Mol Med; 2018 Jun; 22(6):3073-3085. PubMed ID: 29575527
[TBL] [Abstract][Full Text] [Related]
17. The Hippo Pathway and YAP Signaling: Emerging Concepts in Regulation, Signaling, and Experimental Targeting Strategies With Implications for Hepatobiliary Malignancies.
Werneburg N; Gores GJ; Smoot RL
Gene Expr; 2020 Jun; 20(1):67-74. PubMed ID: 31253203
[TBL] [Abstract][Full Text] [Related]
18. New insights into YAP/TAZ nucleo-cytoplasmic shuttling: new cancer therapeutic opportunities?
Shreberk-Shaked M; Oren M
Mol Oncol; 2019 Jun; 13(6):1335-1341. PubMed ID: 31050214
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
